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1. INTRODUCTION 
Cytosine arabinoside (Ara-C, structure 1) is one 
of the drugs widely used in the treatment of leuke- 
mia. Information regarding its capacity to bind 
serum and tissue proteins is invaluable in ascer- 
taining bioavailability which is determined by the 
amount of free drug present in the serum. From 
fluorescence studies, it is found that cytosine 
arabinoside associates with both serum albumin 
and lysozyme with an association constant (K,) of 
2.2 x 104 M-t. In order to characterize the bind- 
ing site and examine the amino acid residues par- 
ticipating in the binding process, proton magnetic 
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resonance studies were undertaken. These results 
indicate the involvement of histidine and the 
cytosine protons of the drug in the association pro- 
cess. The presence of the arabinose moiety also 
plays an important role in the binding. 
2. MATERIALS AND METHODS 
Hen egg white lysozyme, cytosine arabinoside 
and cytosine were all purchased from Sigma 
Chemical Co. (St Louis). 98% Pure heavy water 
(D20) and deuterated hydrochloric acid (DCl) 
were obtained from the Bhabha Atomic Research 
Centre (Bombay). The pH of 4.0 was adjusted 
using DC1 and the pH of the heavy water itself was 
6.8. All solutions were made in D20 at the spec- 
ified pH. The drug concentration was maintained 
as 3 mM in all solutions and [lysozyme] varied 
from 3-0.3 mM in the mixtures. 
The proton magnetic resonance spectra were re- 
corded on a Bruker WH-270 FT NMR spectrome- 
ter operating at 270 MHz for protons at 293 K. 
The number of free induction decays stored and 
Fourier transformed with the help of a BNC-12 
computer with a core memory of 20 K, in each 
case is given in the respective figures. The chemi- 
cal shifts were measured relative to the highest 
field peak of 3,3-dimethyl-4-silapentane sodium 
sulphonate (DSS). 
3. RESULTS 
Studies on the association of Ara-C with 
lysozyme by fluorescence quenching technique in- 
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Fig.1. PMR spectra at 270 MHz of 3 mM Ara-C: (A) proton attached to C(6); (B) proton attached to C(5); (C) H’, ; 
(a) at pH 6.8,37 scans; (b) at pH 4.0,234 scans. 
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Fig.2. PMR spectra of lysozyme at pH 4.0: (a) 3 mM lysozyme at pH 4.0, 230 scans; (b) 5: I ratio of Ara-C and 
lysozyme, 444 scans; (c) 10: 1 ratio of Ara-C and lysozyme, 585 scans; (A-C) correspond to those in fig. 1; 
(D) histidine-15 NH. 
dicke that the drug-protein binding occurs over 
pH 3.8-4.0. Therefore, NMR spectra of Ara-C 
and the various drug-protein mixtures were taken 
at pH 4.0. The spectra of the drug and the protein 
were also recorded separately. The portions of the 
proton spectra between 6-10 ppm downfield from 
the reference are shown in fig. 1 and 2. 
The peak assignments shown in fig.1 correspond 
to those in [l-3]. Each of the cytosine ring protons 
attached to carbons (5) and (6) and the Hi proton 
of the arabinose moiety provides a doublet arising 
from the indirect spin-spin couplings with the 
vicinal protons. The resonances due to the proton 
attached to C(5) and the Hi overlap (tig.lb). The 
experiments at pH 6.8 (fig.la) confirm this point 
since in this case each of these 2 protons provides 
separate doublets. 
The histidine-15 NH proton is clearly seen in 
fig.2a [4-61. The tryptophan NH protons are not 
detectable probably due to exchange with D20. 
The aromatic region of the spectra appeared as a 
complex pattern within the region between 6.5- 
7.5 ppm downfield from the reference (DSS). 
An addition of varying [lysozyme] to fixed [drug] 
(fig.2b) causes a down-field shift of the histidine 
peak. The shift increases with the increase of 
drug-pro?ein ratio from -8.556 ppm without the 
drug to -8.845 ppm when the drug protein ratio is 
10: 1. The proton attached to C(6) shifts up-field 
from -8.04 ppm in the drug spectrum without pro- 
tein to -7.87 ppm in the 1: 1 drug-protein mix- 
ture. The resonances of the proton attached to C(5) 
which overlap with those of the Hi proton in the 
drug spectrum at pH 4.0 separate out as shown in 
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fig2b for the drug-protein ratio of 5: 1. With fur- 
ther increase of drug-protein ratio, the resonances 
due to the proton attached to C(5) slowly move 
down-field and only one of the lines of the proton 
attached to C(5) is observed separately from the Hi 
proton at a drug-protein ratio of 1O:l (fig.2c). 
This means that the resonances due to the drug 
slowly begin to assume the same position as in the 
spectrum of the drug alone at pH 4.0 due to the 
increased concentration of the drug. 
different from the bulk pH. This means that the 
protein is responsible for creating and maintaining 
a particular pH in its interior. 
The aromatic region of the spectrum of lyso- 
zyme is also affected though no definite conclusion 
could be derived from it due to spectral complex- 
ity. The high field region between 0 to -5 ppm 
does not undergo much change and hence it is not 
shown in fig.2. 
The observed shifts of the histidine-15 residue 
and the uptield shifts of both C(6) and C(5) pro- 
tons indicate that these are involved in the binding 
process. Some slight changes in the spectra of the 
aromatic region (such as the broadening and the 
shifts of the spectral lines in the region between 
-7.3 to -7.5 ppm) could mean that the aromatic 
amino acid residues are also participating in the 
binding. Stacking of nucleotide bases with aromat- 
ic amino acids is well-established 19,101 and the 
uptield shifts of the drug resonance point to stack- 
ing interactions in this case also. 
At pH 6.8, the shifts in the histidine peak and 
the resonances of the cytosine and arabinose moi- 
eties follow the same trend as at pH 4.0. 
Similar studies carried out with cytosine and 
lysozyme do not show any spectral changes com- 
pared with the individual spectra of cytosine and 
lysozyme. 
Cytosine itself does not seem to interact with the 
protein whereas Ara-C does cause several changes 
in the protein spectrum. This suggests that the ara- 
binose moiety could be involved in positioning the 
cytosine of the drug at the binding centre. 
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